We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
Cap. Flow
-$23.9M
Cap. Flow %
-0.91%
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$17.5M
2
SYK icon
Stryker
SYK
+$12.2M
3
AZN icon
AstraZeneca
AZN
+$12.1M
4
DHR icon
Danaher
DHR
+$11.9M
5
PFE icon
Pfizer
PFE
+$11.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.6M
2
SHPG
Shire pic
SHPG
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.3M
4
ABT icon
Abbott
ABT
+$10.4M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 94.11%
2 Real Estate 3%
3 Miscellaneous 2.21%
4 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRL icon
126
Charles River Laboratories
CRL
$13.1B
$2.54M 0.1%
22,670
– –
ARDX icon
127
Ardelyx
ARDX
$875M
$2.37M 0.09%
639,370
– –
STE icon
128
Steris
STE
$20.5B
$2.35M 0.09%
22,403
+5,791
+35% +$583K
HSIC icon
129
Henry Schein
HSIC
$9.67B
$2.28M 0.09%
40,035
– –
CBAY
130
DELISTED
Cymabay Therapeutics
CBAY
$2.28M 0.09%
169,962
– –
INVA icon
131
Innoviva
INVA
$1.53B
$2.23M 0.08%
161,603
– –
RARX
132
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.19M 0.08%
219,952
-118,613
-35% -$819K
DERM
133
DELISTED
Dermira, Inc.
DERM
$2.15M 0.08%
234,200
– –
RVNC
134
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.14M 0.08%
77,919
+34,590
+80% +$1.04M
HR
135
DELISTED
Healthcare Realty Trust Incorporated
HR
$1.98M 0.08%
68,000
– –
ONCE
136
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.82M 0.07%
22,046
– –
LOXO
137
DELISTED
Loxo Oncology, Inc
LOXO
$1.8M 0.07%
+10,365
New +$1.56M
ACHN
138
DELISTED
Achillion Pharmaceuticals
ACHN
$1.74M 0.07%
616,000
– –
SGMO
139
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.71M 0.06%
+120,512
New +$2M
TFX icon
140
Teleflex
TFX
$5.42B
$1.71M 0.06%
6,379
+3,897
+157% +$1.04M
SNN icon
141
Smith & Nephew
SNN
$11.6B
$1.66M 0.06%
44,148
– –
ACIU icon
142
AC Immune
ACIU
$263M
$1.6M 0.06%
171,813
– –
ZGNX
143
DELISTED
Zogenix, Inc.
ZGNX
$1.56M 0.06%
+35,352
New +$1.46M
XENE icon
144
Xenon Pharmaceuticals
XENE
$5.5B
$1.51M 0.06%
163,819
-116,181
-41% -$722K
AMRN
145
Amarin Corp
AMRN
$292M
$1.48M 0.06%
23,907
– –
PTGX icon
146
Protagonist Therapeutics
PTGX
$9.24B
$1.47M 0.06%
219,042
– –
TXMD icon
147
TherapeuticsMD
TXMD
$25.2M
$1.46M 0.06%
4,688
-4,687
-50% -$1.43M
ACAD icon
148
Acadia Pharmaceuticals
ACAD
$4.75B
$1.43M 0.05%
93,689
– –
QURE icon
149
uniQure
QURE
$2.95B
$1.43M 0.05%
37,741
-162,009
-81% -$5.19M
SNDX icon
150
Syndax Pharmaceuticals
SNDX
$1.54B
$1.4M 0.05%
200,000
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate and Miscellaneous.

  • Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
  • Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
  • Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
  • Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.